CONTE, Pierfranco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 30.470
EU - Europa 12.659
AS - Asia 4.594
SA - Sud America 44
AF - Africa 34
Continente sconosciuto - Info sul continente non disponibili 14
OC - Oceania 14
Totale 47.829
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 30.407
GB - Regno Unito 4.594
IT - Italia 2.466
CN - Cina 1.619
SE - Svezia 1.326
SG - Singapore 1.134
UA - Ucraina 1.044
DE - Germania 988
IE - Irlanda 898
HK - Hong Kong 781
TR - Turchia 682
FI - Finlandia 488
BG - Bulgaria 380
FR - Francia 155
IN - India 131
BE - Belgio 66
ID - Indonesia 63
RU - Federazione Russa 61
VN - Vietnam 58
CA - Canada 49
NL - Olanda 32
BR - Brasile 29
LT - Lituania 28
IR - Iran 25
MY - Malesia 25
ES - Italia 18
JP - Giappone 18
CZ - Repubblica Ceca 16
AU - Australia 14
CH - Svizzera 13
KR - Corea 13
AL - Albania 12
RO - Romania 12
TW - Taiwan 12
EU - Europa 10
PL - Polonia 10
GR - Grecia 9
MX - Messico 9
CL - Cile 7
ET - Etiopia 7
HU - Ungheria 7
IQ - Iraq 7
AT - Austria 6
MK - Macedonia 6
EG - Egitto 5
MA - Marocco 5
NG - Nigeria 5
BZ - Belize 4
DK - Danimarca 4
KE - Kenya 4
SI - Slovenia 4
TH - Thailandia 4
A2 - ???statistics.table.value.countryCode.A2??? 3
BD - Bangladesh 3
BO - Bolivia 3
IL - Israele 3
NO - Norvegia 3
AE - Emirati Arabi Uniti 2
AM - Armenia 2
BH - Bahrain 2
EC - Ecuador 2
LV - Lettonia 2
LY - Libia 2
MD - Moldavia 2
PH - Filippine 2
PK - Pakistan 2
PT - Portogallo 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
AF - Afghanistan, Repubblica islamica di 1
AN - Antille olandesi 1
AP - ???statistics.table.value.countryCode.AP??? 1
AR - Argentina 1
BJ - Benin 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
KH - Cambogia 1
LB - Libano 1
LI - Liechtenstein 1
ME - Montenegro 1
MZ - Mozambico 1
NP - Nepal 1
PE - Perù 1
SA - Arabia Saudita 1
UZ - Uzbekistan 1
VE - Venezuela 1
ZA - Sudafrica 1
Totale 47.829
Salva come PNG Salva come JPEG
Città #
Fairfield 4.172
Southend 3.802
Woodbridge 3.069
Houston 2.589
Jacksonville 2.272
Chandler 2.036
Ashburn 1.921
Ann Arbor 1.736
Dearborn 1.571
Seattle 1.514
Wilmington 1.476
Cambridge 1.374
Santa Clara 1.306
Dublin 896
Singapore 862
Nyköping 827
Hong Kong 770
Modena 622
Beijing 546
Princeton 444
San Diego 421
Eugene 379
Sofia 379
Izmir 361
Des Moines 201
New York 192
Milan 163
Helsinki 145
Falls Church 142
London 141
Boardman 110
Shanghai 106
Rome 100
Norwalk 91
Brussels 64
Bologna 61
Jakarta 60
Hefei 58
Redwood City 57
Dong Ket 54
Fremont 51
Bremen 49
Munich 42
Nanjing 42
Turin 40
Kilburn 38
Naples 38
Guangzhou 36
Kunming 36
Hounslow 33
San Mateo 33
Bari 26
Padova 24
Verona 24
Ottawa 23
Phoenix 22
Vicenza 21
Chiswick 20
Florence 20
Frankfurt am Main 20
Genoa 20
Indiana 20
Nanchang 19
Palermo 19
Catania 18
Wuhan 18
Los Angeles 17
Reggio Emilia 17
Dallas 16
Jinan 16
Toronto 16
Zhengzhou 16
Fulham 15
Parma 15
Mountain View 14
Shenyang 14
Tappahannock 14
Philadelphia 13
San Giuliano Milanese 13
Chicago 12
Monmouth Junction 12
Piacenza 12
Ardabil 11
Bangalore 11
Cagliari 11
Islington 11
Lansdale 11
Leawood 11
Paris 11
Pisa 11
Augusta 10
Prescot 10
Ravenna 10
Saint Petersburg 10
Amsterdam 9
Brno 9
Chengdu 9
Hebei 9
Madrid 9
Mumbai 9
Totale 38.256
Salva come PNG Salva come JPEG
Nome #
VALORE PROGNOSTICO E PREDITTIVO DI p53 NEL CARCINOMA MAMMARIO TRATTATO CON CHEMIOTERAPIA NEOADIUVANTE 720
ShortHER: TRATTAMENTO ADIUVANTE CON HERCEPTIN PER 3 MESI VERSO 12 MESI, IN ASSOCIAZIONE CON DUE DIFFERENTI REGIMI DI CHEMIOTERAPIA, NELLE PAZIENTI CON CARCINOMA MAMMARIO HER2 POSITIVO 313
MSC-delivered soluble TRAIl and paclitaxel as novel combinatory treatment for pancreatic adenocarcinoma 301
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 292
Rigenerand srl - Spin off Università di Modena e Reggio Emilia 269
Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer 268
A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing 254
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. 250
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial . 249
Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-Sensitive, HER2-Negative Operable Breast Cancer: A Double-Blind, Randomized Phase II Study with Biomarker Evaluation (EGF109077-LAP107692/LETLOB) 248
SOLUBLE TRAIL-ARMED HUMAN AD-MSC AS NOVEL CELL THERAPY APPROACH FOR PANCREATIC DUCTAL ADENOCARCINOMA 236
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. 231
MSC and Tumors: Homing, Differentiation and Secretion Influence The Therapeutic Potentials 229
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus 228
Isolation, characterization, and transduction of endometrial decidual tissue multipotent mesenchymal stromal/stem cells from menstrual blood 226
Le Cellule Staminali Mesenchimali: Aspetti Biologici ed Approcci Terapeutici 226
Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer 221
A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study) 219
METHOD FOR PRODUCTION OF ANTI-TUMOR TRAIL PROTEIN 218
Mesenchymal progenitors aging highlights a mir-196 switch targeting HOXB7 as master regulator of proliferation and osteogenesis 214
MODULAZIONE DELL’ESPRESSIONE DI BIOMARCATORI E PROGNOSI IN PAZIENTI AFFETTE DA CARCINOMA MAMMARIO OPERABILE SOTTOPOSTE A CHEMIOTERAPIA PREOPERATORIA 212
Restoration and reversible expansion of the osteoblastic hematopoietic stem cell niche after marrow radioablation 208
Mesenchymal progenitors expressing TRAIL induce apoptosis in sarcomas 208
Phase I study of intraperitoneal MHC unrestricted adoptive cell therapy with TALL-104 cells in patients with peritoneal carcinosis 207
FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer 204
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy. 203
Immune characterization of breast cancer metastases: prognostic implications. 202
Significance of lymph node sampling in epithelial carcinoma of the ovary. 201
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. 200
Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer.. 198
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 196
GMP-manufactured density gradient media for optimized mesenchymal stromal/stem cell isolation and expansion. 195
Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis 193
Cytogenetic abnormalities and clinical features in a patient cohort affected by three or more synchronous or metachronous primitive malignancies. 193
Achievements and unmet needs in the management of advanced ovarian cancer 192
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. 191
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients 190
Timing for starting second line therapy in recurrent ovarian cancer. 189
Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial). 189
Prognostic and Predictive Value of Baseline and Posttreatment Molecular Marker Expression in Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiotherapy 185
Double-blind, placebo-controlled, multicentric randomized phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal HER2-negative, hormone receptor-positive operable breast cancer 182
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis 182
Preoperative chemotherapy plus lapatinib or trastuzumab or both in Her2 positive operable breast cancer. EGF109085-LAP106988/CHERLOB Trial. 181
A dose-finding study of ifosfamide by three-day continuous infusion in pretreated, advanced breast cancer patients. 180
CHER LOB Trial: Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer--Safety report as per Independent Data Monitoring Committee (IDMC) and preliminary activity data 180
Rare breast cancer subtypes: Histological, molecular, and clinical peculiarities 179
Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial 177
Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer 176
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer 175
Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy. 175
Prognostic value of Dworak grade of regression (GR) in patients with rectal carcinoma treated with preoperative radiochemotherapy 171
3* Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer 171
Donor Cell-Derived Osteopoiesis Originates from a Self-Renewing Stem Cell with a Limited Regenerative Contribution after Transplantation 170
Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. 169
Incidence and clinical impact of sterilized disease and minimal residual disease after preoperative radiochemotherapy for rectal cancer 167
A prognostic model based on nodal status and Ki 67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 167
Primary adrenal gland carcinosarcoma associated with metastatic rectal cancer: a hitherto unreported collision tumor 166
Chemotherapy versus radiotherapy in the management of ovarian cancer patients with pathological complete response or minimal residual disease at second look. 165
Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria 165
Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment. 164
Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design. 163
Gastrointestinal stromal tumor and other primary metachronous and synchronous neoplasms as a suspicious criterion for syndromic setting 162
Triple-negative breast cancer: current management and future options. 162
Device for cell culture 160
Ki67 as a Predictor of Response and Long Term Survival in Hormone Receptor Positive/HER2 Negative Breast Cancer Patients Treated with Preoperative Chemotherapy 160
The sequential use of endocrine treatment for advanced breast cancer: where are we? 159
Treatment of large HCC: transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization. 157
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study 157
Cardiotoxicity of Epirubicin/Paclitaxel Containing Regimens: Role of Cardiac Risk Factors 156
Paclitaxel and vinorelbine in anthracycline pretreated breast cancer: a phase II study. 156
Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies. 156
Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: A case report 156
Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2 positive operable breast cancer: results of the randomized phase II CHER-LOB study 156
Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma 155
A phase I-II study of oral doxifluridine plus radiotherapy in radiosensitive tumors of the pelvic region. 155
Neoadjuvant treatment with Single – Agent Cetuximab Followed by 5-Fu, Cetuximab, and Pelvic Radiotherapy: A Phase II Study in Locally Advanced Rectal Cancer. 154
Accelerated epirubicin-ifosfamide-dacarbazine regimen in patients with adult soft tissue sarcomas. 153
Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. 153
Biomarkers predicting clinical benefit: fact or fiction? 152
Management and treatment of triple-negative breast cancer patients from the NEMESI study: an Italian experience. 151
Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer 150
The clinical relevance of endocrine therapy induced changes in lipid metabolism in breast cancer patients 150
Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM 149
Prognostic value of "Dworak" tumor regression grade (TRG) after pre-operative chemo-radiotherapy in rectal cancer (RC) 148
High – dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study 148
Intraperitoneal versus Intravenous Cisplatin in Combination with Intravenous Cyclophosphamide and Epidoxorubicin in Optimally Cytoreduced Advanced Epithelial Ovarian Cancer: A randomized trial of the Gruppo Oncologico Nord Ovest. 147
Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. 147
Phase II study of oral doxifluridine in elderly patients with advanced non-small-cell lung cancer. 147
Primary Systemic Therapy in operable breast cancer: clinical data and biological fall-out 146
Bevacizumab treatment for advanced breast cancer. 146
International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). 146
Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer 145
Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. 145
Magnetic resonance imaging and ultrasonography in predicting pathologic extent after preoperative chemotherapy in stage II-III breast cancer 145
Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study 145
Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy 145
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials (Breast Cancer Research and Treatment, (2017), 163, 2, (295-302), 10.1007/s10549-017-4191-y) 145
Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: A pilot study in patients with metastatic colorectal cancer 144
9 Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study Short-HER. 144
Advanced ovarian cancer in the elderly: Results of consecutive trials with cisplatin-based chemotherapy 144
Totale 18.889
Salva come PNG Salva come JPEG
Categoria #
all - tutte 200.066
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 200.066
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20207.405 0 0 0 0 1.187 1.561 1.598 865 885 272 575 462
2020/20216.646 688 329 691 504 730 397 617 874 264 846 396 310
2021/20226.219 88 931 783 382 147 259 445 325 648 469 962 780
2022/20236.351 741 573 316 510 659 906 77 541 1.521 83 257 167
2023/20243.774 182 248 204 229 705 349 393 705 125 114 163 357
2024/20253.114 362 159 183 872 1.538 0 0 0 0 0 0 0
Totale 48.187